SCHEMBL24288138

SCHEMBL24288138

Cc1nc(NC2CCCOC2)ncc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 3/20 0.47
▸ MAPK9 P45984 3/20 0.47
▸ IDH1 O75874 1/20 0.44
▸ MKNK1 Q9BUB5 2/20 0.42
▸ MKNK2 Q9HBH9 2/20 0.42
▸ MAPK1 P28482 4/20 0.42
▸ MAPK10 P53779 2/20 0.39
▸ GBA1 P04062 1/20 0.38
▸ HDAC3 O15379 2/20 0.37
▸ HDAC1 Q13547 2/20 0.37
▸ HDAC2 Q92769 2/20 0.37
▸ HDAC6 Q9UBN7 2/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ KAT2B Q92831 1/20 0.36
▸ IGF1R P08069 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ ULK1 O75385 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ PAK1 Q13153 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17151392 0.75 MKNK1 (0.55) MAPK8MAPK9IDH1MKNK1MKNK2
SCHEMBL12367071 0.74 IGF1R (0.55) MAPK8MKNK1MAPK1IRAK4IGF1R
SCHEMBL2300387 0.73 KMT2A (0.48) MAPK8MAPK9IDH1MKNK1MKNK2
SCHEMBL31547075 0.70 MAPK1 (0.56) MKNK1MKNK2MAPK1HDAC3HDAC1
SCHEMBL12237655 0.70 MAPK1 (0.56) MKNK1MKNK2MAPK1HDAC3HDAC1
SCHEMBL24103627 0.70 MAPK1 (0.81) MAPK8MAPK9MKNK1MKNK2MAPK1
SCHEMBL28742064 0.69 MAPK8 (0.46) MAPK8MAPK9IDH1MKNK1MKNK2
SCHEMBL13734398 0.69 MAPK8 (0.56) MAPK8MAPK9IDH1MKNK1MKNK2
SCHEMBL17148506 0.69 MKNK1 (0.52) MAPK8MAPK9IDH1MKNK1MKNK2
SCHEMBL14659058 0.68 MAPK8 (0.81) MAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240059677-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR CEREVANCE LTD (GB) 2024-02-22 — — US disclosed
WO-2022053823-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR Cerevance, Inc. (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059677-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR CHRNA6, CHRM2, CHRNA1 MAPK8 4241/4885MAPK9 3680/4885IDH1 1145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback